CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity

International Journal of Oncology

Volumn 30, Issue 3, 2007, Pages 631-639

  Turnquist, Heth R ^a,b,c   Lin, Xuede ^a   Ashour, Abdelkader E ^a,b   Hollingsworth, Michael A ^a,b   Singh, Rakesh K ^b   Talmadge, James E ^b   Solheim, Joyce C ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

CCL21; Chemokine; Dendritic cell; Pancreatic cancer; Tumor immunology

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CHEMOKINE; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MOUSE; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SPLEEN;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOKINES, CC; FEMALE; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROGNOSIS; SPLEEN;

EID: 33947722716     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.3.631     Document Type: Article

References (47)

1. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT and Nakano H: Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189: 451-460, 1999.
2. Bjorkdahl O, Barber KA, Brett SJ, Daly MG, Plumpton C, Elshourbagy NA, Tite JP and Thomsen LL: Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues. Immunology 110: 170-179, 2003.
3. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S and Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188: 373-386, 1998.
4. Johnston B, Kim CH, Soler D, Emoto M and Butcher EC: Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 171: 2960-2969, 2003.
5. Kim CH, Johnston B and Butcher EC: Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100: 11-16, 2002.
6. Sallusto F, Lenig D, Forster R, Lipp M and Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712, 1999. (Pubitemid 129515761)
7. Vitale M, Della Chiesa M, Carlomagno S, Romagnanci C, Thiel A, Moretta L and Moretta A: The small subset of CD56brightCD16-natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 34: 1715-1722, 2004. (Pubitemid 39256054)
8. Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, Nishimura M, Kakizaki M, Nomiyama H and Yoshie O: Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem 272: 13803-13809, 1997. (Pubitemid 27224818)
9. Yoshida R, Nagira M, Imai T, Baba M, Takagi S, Tabira Y, Akagi J, Nomiyama H and Yoshie O: EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. Int Immunol 10: 901-910, 1998. (Pubitemid 28325606)
10. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD and Williams LT: A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naïve T lymphocytes. Proc Natl Acad Sci USA 95: 258-263, 1998. (Pubitemid 28103941)
11. Stein JV, Rot A, Luo Y, Narasimhaswamy M, Nakano H, Gunn MD, Matsuzawa A, Quackenbush EJ, Dorf ME and von Andrian UH: The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J Exp Med 191: 61-76, 2000.
12. Yanagawa Y and Onoe K: CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 101: 4923-4929, 2003.
13. Soto H, Wang W, Strieter RM, Copeland NG, Gilbert DJ, Jenkins NA, Hedrick J and Zlotnik A: The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci USA 95: 8205-8210, 1998.
14. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A and Caux C: Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 165: 1992-2000, 2000.
15. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L and Mule JJ: T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61: 2062-2070, 2001.
16. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK and Dubinett SM: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164: 4558-4563, 2000.
17. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, Huang M, Strieter R and Dubinett SM: Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 61: 6406-6412, 2001.
18. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM and Dubinett SM: SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2: 22, 2003.
19. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM and Sharma S: Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10: 2891-2901, 2004.
20. Kirk CJ, Hartigan-O'Connor D and Mule JJ: The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61: 8794-8802, 2001.
21. Cancer FACTS and Figures. American Cancer Society, Atlanta, GA, 2004.
22. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
23. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S and Katoh H: CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: 326-331, 2004.
24. Dallal RM, Christakos P, Lee K, Egawa S, Son YI and Lotze MT: Paucity of dendritic cells in pancreatic cancer. Surgery 131: 135-138, 2002.
25. Fonteneau JF, Kavanagh DG, Lirvall M, Sanders C, Cover TL, Bhardwaj N and Larsson M: Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102: 4448-4455, 2003.
26. Guiducci C, Di Carlo E, Parenza M, Hitt M, Giovarelli M, Musiani P and Colombo MP: Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 172: 4026-4036, 2004.
27. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr and Schabel FM Jr: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44: 717-726, 1984.
28. Winn HJ: Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 86: 228-239, 1961.
29. Vremec D and Shortman K: Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 159: 565-573, 1997.
30. Jung TM, Gallatin WM, Weissman IL and Dailey MO: Down-regulation of homing receptors after T cell activation. J Immunol 141: 4110-4117, 1988.
31. Unsoeld H, Krautwald S, Voehringer D, Kunzendorf U and Pircher H: Cutting edge: CCR7+ and CCR7- memory T cells do not differ in immediate effector cell function. J Immunol 169: 638-641, 2002.
32. Shimizu J, Yamazaki S and Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
33. Fu S, Yopp AC, Mao X, Chen D, Zhang N, Mao M, Ding Y and Bromberg JS: CD4+CD25+CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 4: 65-78, 2004.
34. You S, Slehoffer G, Barriot S, Bach JF and Chatenoud L: Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA 101 (Suppl 2): 14580-14585, 2004.
35. O'Keeffe M, Hochrein H, Vremec D, Scott B, Hertzog P, Tatarczuch L and Shortman K: Dendritic cell precursor populations of mouse blood: identification of the murine homologues of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood 101: 1453-1459, 2003.
36. Whiteside TL and Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53: 240-248, 2004.
37. Maldonado-Lopez R, Maliszewski C, Urbain J and Moser M: Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo. J Immunol 167: 4345-4350, 2001.
38. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E and Maliszewski CR: Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 96: 1036-1041, 1999.
39. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal, Malefyt R and Liu YJ: Reciprocal control of T helper cell and dendritic cell differentiation. Science 283: 1183-1186, 1999. (Pubitemid 129504124)
40. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu YJ, and O'Garra A: Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 197: 101-109, 2003. (Pubitemid 36110261)
41. Barth RJ Jr, Mule JJ, Spiess PJ and Rosenberg SA: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647-658, 1991.
42. Grufman P and Karre K: Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol 30: 1088-1093, 2000. (Pubitemid 30216225)
43. den Haan JM, Lehar SM and Bevan MJ: CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 192: 1685-1696, 2000.
44. Nakano H, Yanagita M and Gunn MD: CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 194: 1171-1178, 2001. (Pubitemid 32995786)
45. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW and Storkus WJ: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196: 619-628, 2002. (Pubitemid 35024440)
46. Kim CH, Pelus LM, Appelbaum E, Johanson K, Anzai N and Broxmeyer HE: CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. Cell Immunol 193: 226-235, 1999. (Pubitemid 29228369)
47. Arenberg DA, Zlotnick A, Strom SR, Burdick MD and Strieter RM: The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model. Cancer Immunol Immunother 49: 587-592, 2001.